カテゴリ： GlobalData, アメリカ, 企業調査

Puma Biotechnology Inc (PBYI)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Puma Biotechnology Inc (PBYI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9953
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：87
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Puma Biotechnology Inc (Puma) is a biopharmaceutical company that develops novel therapeutics for the treatment of cancer. The company develops and commercializes three drug candidates, namely, PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Its pipeline portfolio also encompasses investigational candidates for various indications such as adjuvant breast cancer, gastric cancer, metastatic breast cancer, and HER2-positive breast cancer, among others. Puma in-licenses its drug candidates and advances its development through clinical testing and for commercial use. Puma is headquartered in Los Angeles, California, the US.

Puma Biotechnology Inc (PBYI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 6
Puma Biotechnology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Puma Biotechnology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Puma Biotechnology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Puma Biotechnology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Puma Biotechnology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Puma Biotechnology Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Celcuity Enters into Agreement with Puma Biotechnology and West Cancer Center 12
Puma Biotechnology and Strata Oncology Enter into Collaboration Agreement 13
Champions Oncology Enters into Agreement with NSABP Foundation and Puma Biotechnology 14
Daiichi Sankyo and Puma Biotech Enter into Research Agreement with Memorial Sloan Kettering Cancer Center 15
Licensing Agreements 16
Pint Pharma Enters into Licensing Agreement with Puma Biotech 16
Medison Pharma Enters into Licensing Agreement with Puma Biotechnology 17
CANbridge Life Sciences Enters into Licensing Agreement with Puma Biotechnology 18
Puma Biotechnology Enters into Licensing Agreement with Specialised Therapeutics 19
Equity Offering 20
Puma Biotech Raises USD172.5 Million in Public Offering of Shares 20
Puma Biotech Raises USD218.5 Million in Public Offering of Shares 22
Puma Biotech Completes Public Offering Of Shares For US$138 Million 24
Puma Biotech Completes Public Offering Of Common Stock For US$138 Million 25
Puma Biotechnology Inc – Key Competitors 27
Puma Biotechnology Inc – Key Employees 28
Puma Biotechnology Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Aug 09, 2018: Puma Biotechnology reports second quarter 2018 financial results 30
May 09, 2018: Puma Biotechnology Reports First Quarter 2018 Financial Results 32
Mar 01, 2018: Puma Biotechnology Announces Fourth Quarter and Full Year 2017 Financial Results 34
Nov 09, 2017: Puma Biotechnology Reports Third Quarter 2017 Financial Results 37
Aug 09, 2017: Puma Biotechnology Reports Second Quarter 2017 Financial Results 38
May 10, 2017: Puma Biotechnology Reports First Quarter 2017 Financial Results 40
Mar 01, 2017: Puma Biotechnology Reports Fourth Quarter and Full Year 2016 Financial Results 42
Corporate Communications 44
Dec 14, 2017: Puma Biotechnology Added to NASDAQ Biotechnology Index 44
Product News 45
12/13/2017: Puma Biotechnology Announces Meeting of Scientific Advisory Group on Oncology in Europe to Review Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer 45
11/02/2017: Puma Biotechnology Secures $100 Million Term Loan from Silicon Valley Bank and Oxford Finance 46
09/04/2018: European Commission grants marketing authorisation for Puma Biotechnology’s NERLYNX (neratinib) for extended adjuvant treatment of hormone receptor positive HER2-positive early stage breast cancer 47
08/03/2017: Investigators match novel cancer mutations with potential therapies 48
07/31/2017: Puma Announces Availability of NERLYNX (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in the United States 49
07/21/2017: NERLYNX (neratinib) Tablets Approved for HER2+ Breast Cancer in the Extended Adjuvant Setting 50
07/17/2017: FDA approves new treatment to reduce the risk of breast cancer returning 51
07/17/2017: U.S. Food and Drug Administration Approves Puma’s NERLYNX (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer 52
06/29/2018: Puma Biotechnology Receives Positive CHMP Opinion Recommending Approval of NERLYNX for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer 53
06/26/2018: Puma Biotechnology Announces Results of CHMP Reexamination of MAA for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer 54
06/02/2018: Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2018 ASCO Annual Meeting 55
04/17/2017: Puma Biotechnology Announces FDA Advisory Committee to Review Neratinib for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer 56
04/12/2017: Caligor to Support Puma Biotechnology’s Expanded Access Program for PB272 (Neratinib) in the United States 57
04/05/2018: Specialised Therapeutics Asia Initiates Early Access Program For Neratinib 58
04/02/2018: NCCN Guidelines for Central Nervous System Cancers Include NERLYNX (neratinib) in Combination with Capecitabine or Paclitaxel as Treatment Options for Patients with Breast Cancer Brain Metastases 59
04/02/2017: Puma Biotechnology Launches Expanded Access Program for PB272 (Neratinib) for U.S. Patients with HER2-Positive Breast Cancer or HER2-Mutated Cancer 60
04/02/2017: Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2017 AACR Annual Meeting 61
03/23/2018: Puma Biotechnology Requests Re-examination of Recommendation on Nerlynx 62
02/23/2018: Puma Biotechnology Receives Results of CHMP Formal Decision for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer 63
Product Approvals 64
Jul 31, 2018: Puma Biotechnology Files New Drug Submission for NERLYNX in Canada 64
Jan 23, 2018: Puma Biotechnology Announces Results of CHMP Oral Explanation for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer 65
Aug 02, 2017: Puma Biotechnology Receives Day-180 List of Outstanding Issues from Committee for Medicinal Products for Human Use (CHMP) 66
May 24, 2017: Puma Biotechnology Receives FDA Advisory Committee Support for Neratinib 67
May 22, 2017: Puma Biotechnology Announces Posting of FDA Oncologic Drugs Advisory Committee Briefing Documents for Neratinib Meeting 68
Clinical Trials 69
May 24, 2018: Researchers awarded multiple Department of Defense grants in next frontier of breast cancer genomics 69
Jan 31, 2018: Puma Biotechnology Announces Publication of Results from Phase II SUMMIT ‘Basket’ Trial Evaluating Neratinib in HER2 and HER3 Mutant Cancer 71
Dec 06, 2017: Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2017 San Antonio Breast Cancer Symposium 72
Nov 13, 2017: Puma Biotechnology’s 5-Year Analysis of Phase III ExteNET Study Published Online in The Lancet Oncology 74
Sep 12, 2017: US Oncology Research Plays an Important Role in the Clinical Development for NERLYNX Tablets 75
Sep 08, 2017: Puma Biotechnology Presents 5-Year Analysis of Phase III ExteNET Trial in Extended Adjuvant HER2-Positive Breast Cancer at ESMO 2017 Congress 76
Aug 30, 2017: Puma Biotechnology Announces Publication of Abstracts for ESMO 2017 78
Jul 06, 2017: Puma Biotechnology Completes Targeted Enrollment in Neratinib Phase III Metastatic Breast Cancer Trial 79
Jun 03, 2017: Puma Biotechnology Announces Positive PB272 Phase II Data from TBCRC 022 Trial in Patients with HER2-Positive Metastatic Breast Cancer with Brain Metastases at the 2017 ASCO Annual Meeting 80
May 17, 2017: Puma Biotechnology Announces Publication of Neratinib Abstract for the 2017 ASCO Annual Meeting 81
Apr 04, 2017: Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of PB272 in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2017 AACR Annual Meeting 82
Apr 02, 2017: Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Cancer at the 2017 AACR Annual Meeting 84
Mar 01, 2017: Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2017 85
Jan 06, 2017: Puma Biotechnology Expands Cohort in Phase II SUMMIT Trial of PB272 in HER2 Mutation-Positive Cancer Patients 86
Appendix 87
Methodology 87
About GlobalData 87
Contact Us 87
Disclaimer 87

List of Tables
Puma Biotechnology Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Puma Biotechnology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Puma Biotechnology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Puma Biotechnology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Puma Biotechnology Inc, Deals By Therapy Area, 2012 to YTD 2018 10
Puma Biotechnology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Celcuity Enters into Agreement with Puma Biotechnology and West Cancer Center 12
Puma Biotechnology and Strata Oncology Enter into Collaboration Agreement 13
Champions Oncology Enters into Agreement with NSABP Foundation and Puma Biotechnology 14
Daiichi Sankyo and Puma Biotech Enter into Research Agreement with Memorial Sloan Kettering Cancer Center 15
Pint Pharma Enters into Licensing Agreement with Puma Biotech 16
Medison Pharma Enters into Licensing Agreement with Puma Biotechnology 17
CANbridge Life Sciences Enters into Licensing Agreement with Puma Biotechnology 18
Puma Biotechnology Enters into Licensing Agreement with Specialised Therapeutics 19
Puma Biotech Raises USD172.5 Million in Public Offering of Shares 20
Puma Biotech Raises USD218.5 Million in Public Offering of Shares 22
Puma Biotech Completes Public Offering Of Shares For US$138 Million 24
Puma Biotech Completes Public Offering Of Common Stock For US$138 Million 25
Puma Biotechnology Inc, Key Competitors 27
Puma Biotechnology Inc, Key Employees 28
Puma Biotechnology Inc, Subsidiaries 29

List of Figures
Puma Biotechnology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Puma Biotechnology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Puma Biotechnology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Puma Biotechnology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Puma Biotechnology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Puma Biotechnology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Puma Biotechnology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Puma Biotechnology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

★海外企業調査レポート[Puma Biotechnology Inc (PBYI)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Corus Entertainment Inc. (CJR.B)：企業の財務・戦略的SWOT分析
    Corus Entertainment Inc. (CJR.B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Can-Fite BioPharma Ltd (CANF)：企業の財務・戦略的SWOT分析
    Summary Can-Fite BioPharma Ltd (Can-Fite) is a clinical stage drug development Company that strives to develop small molecule drugs for the treatment of cancer and inflammatory diseases. The company’s pipeline products which are in phase II and III clinical development stage includes CF101, for rheu …
  • Wien Energie GmbH：企業の戦略的SWOT分析
    Wien Energie GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Komatsu Ltd (6301)：企業の財務・戦略的SWOT分析
    Komatsu Ltd (6301) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Lion Energy Ltd (LIO)：企業の財務・戦略的SWOT分析
    Summary Lion Energy Ltd (Lion) is an oil and gas company that explores, develops and produces unconventional oil and gas resources in Indonesia. The company has conventional production sharing contracts such as Seram project and South Block A project. Its Seram project is located on the island of Se …
  • Twilio Inc (TWLO)：企業の財務・戦略的SWOT分析
    Twilio Inc (TWLO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Biogen Inc (BIIB)：企業の財務・戦略的SWOT分析
    Biogen Inc (BIIB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Elbit Imaging Ltd：医療機器：M&Aディール及び事業提携情報
    Summary Elbit Imaging Ltd (Elbit), formerly Elbit Medical Imaging Ltd is a diversified company that operates through various business segments including commercial centers, hotel, medical industries and devices, and plots in India. The company’s commercial centers segment includes initiation, constr …
  • Kinross Gold Corporation：企業のM&A・事業提携・投資動向
    Kinross Gold Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Kinross Gold Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • 2-BBB Medicines BV：製薬・医療：M&Aディール及び事業提携情報
    Summary 2-BBB Medicines BV (2-BBB), formerly to-BBB Therapeutics BV is a biotechnology company that develops medicines for the treatment of brain cancer and neuro-inflammatory diseases. The company develops medicines using its proprietary liposomal drug delivery platform, G-Technology. Its pipeline …
  • Oil States Industries Inc：石油・ガス：M&Aディール及び事業提携情報
    Summary Oil States Industries Inc (Oil States), a subsidiary of Oil States International Inc, is a provider of intergrated energy systems and solutions that offers oil and gas products and services. The company provides products in the areas of offshore, onshore, marine and industrial areas, among o …
  • PT Kimia Farma (Persero) Tbk (KAEF)：企業の財務・戦略的SWOT分析
    PT Kimia Farma (Persero) Tbk (KAEF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Occidental Petroleum Corporation (OXY)-エネルギー分野：企業M&A・提携分析
    Summary Occidental Petroleum Corporation (Occidental) is an oil and gas exploration and production company with integrated assets. The company is active in upstream exploration and production; midstream and marketing; and chemicals business. The oil and gas business explores for, develops and produc …
  • Maple Leaf Foods Inc (MFI)：企業の財務・戦略的SWOT分析
    Maple Leaf Foods Inc (MFI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Petrel Resources Plc (PET)：石油・ガス：M&Aディール及び事業提携情報
    Summary Petrel Resources Plc (Petrel Resources) is an oil and gas company that provides exploration and production of crude oil and natural gas across Iraq. The company provides areas of operations such as Luhais and Subba in Southern Iraq, Tano Basin in Ghana, Porcupine Basin in Ireland, and others …
  • African Development Bank Group：企業の戦略的SWOT分析
    African Development Bank Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • ENCE Energia Y Celulosa SA (ENC)：企業の財務・戦略的SWOT分析
    ENCE Energia Y Celulosa SA (ENC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • ULURU Inc (ULUR)：企業の財務・戦略的SWOT分析
    Summary ULURU Inc (ULURU) operates as a medical technology company that researches, develops, and markets wound care and muco-adhesive film products. The company’s products include Altrazeal and OraDisc. Its Altrazeal is a transforming powder dressing with Nanoflex technology for the management of e …
  • Hainan Airlines Co., Ltd.：企業のM&A・事業提携・投資動向
    Hainan Airlines Co., Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Hainan Airlines Co., Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisi …
  • CiToxLAB Group：製薬・医療：M&Aディール及び事業提携情報
    Summary CiToxLab Group (CiToxLab) is a contract research organization that provides preclinical and specialty services. The company provides toxicology and safety pharmacology, biomarkers, pharmacokinetics, immunology services, surgical models and medical device implantation, animal efficacy models, …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆